SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPorvair Regulatory News (PRV)

Share Price Information for Porvair (PRV)

Share Price is delayed by 15 minutes
Get Live Data
830.00    14.00 (1.72%)
Bid:
824.00
Ask:
828.00
Spread: 4.00 (0.485%)
Market Cap: £382.60m
PRV Live PriceLast checked at - London Stock Exchange

Intraday Porvair Share Chart

Trading Update and Covid-19 Statement

8 Apr 2020 07:00

RNS Number : 1263J
Porvair PLC
08 April 2020
Ā 

For immediate release 8 April 2020

Ā 

Porvair plc

("Porvair" or the "Group")

Ā 

Trading Update and Covid-19 Statement

Porvair plc ("Porvair" or "the Group"), the specialist filtration and environmental technology group, today issues a trading update and comment on COVID-19.

The overriding priority for Porvair management teams over the last few weeks has been the wellbeing of staff and their families. Health and safety guidelines for each country are being followed and physical distancing at work is being observed. Staff in China remained on full pay throughout a seven week shut-down and are now all back at work. Where staff members elsewhere in the Group have needed to self-isolate similar arrangements have been made.

Porvair is doing what it can to help governments and health services. We are supplying filter components for several of the consortia now building ventilator and breathing apparatus: one in France; one in Sweden; three in the US; and the Mercedes AMG/Formula 1 consortium in the UK. Porvair is supplying consumables for dozens of US testing laboratories, including the Mayo Clinic; is producing millions of pipette tips for COVID-19 testing kits; and thousands of filters for Diagnostics in the Real World. Shifts have been added to produce chromatography bed supports and pharmaceutical grade water filters. The Board anticipates further programmes will emerge as the crisis continues. Whilst these orders are relatively small they illustrate the capabilities and commitment of our staff.

In financial terms, the impact on the Group will depend on the duration of the COVID-19 pandemic and on the severity of its economic consequences. The Board of Porvair has considered various outlook scenarios, stress testing the Group for different levels of challenge, plant by plant. The Group has a strong balance sheet and is expected to be both profitable and modestly cash generative through the balance of the year in all but the most pessimistic scenarios. The Board does not believe it needs to change its final dividend recommendation.

In its outlook statement dated 31 January 2020 the Group noted its positive exposure to global growth trends including tighter environmental regulations; growth in analytical science; the expansion of air travel; the replacement of plastic by aluminium and the drive for manufacturing process efficiency. Looking to 2021 and beyond the Group expects these trends to continue. Indeed, 2020 has started well with revenues ahead of the prior year in the four months to the end of March. All plants are currently open and April is busy. However, there will no doubt be disruption during the rest of the year. Demand, in sectors including aviation, automotive and industrial manufacturing, is likely to decline. Other sectors, mainly in the Laboratory division, are expected to remain busy. As we wait to see how the economic consequences of COVID 19 develop, the Board therefore considers it prudent to withdraw guidance until the outlook is more certain.

Should the situation change significantly, the Group will issue a further update at its AGM on 21 April 2020.

For further information, please contact:

Porvair plc

Ā 

01553 765 500

Ben Stocks, Group Chief Executive

Chris Tyler, Group Finance Director

Ā 

Ā 

Buchanan Communications

Ā 

0207 466 5000

Charles Ryland / Steph Watson

Ā 

Ā 

Ā 

Notes to editors

Ā 

Porvair plc

Porvair is a group of specialist filtration and environmental technology businesses. Its businesses design and manufacture a range of bespoke consumable filtration products that are used in a range of niche filtration markets. It operates in three divisions: Aerospace & Industrial; Laboratory; and Metal Melt Quality.

Ā 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Ā 
END
Ā 
Ā 
MSCEAKLXESLEEFA
Date   Source Headline
27th Mar 20257:00 amRNSGrant of SAYE Options
18th Mar 20257:40 amRNSHolding(s) in Company
17th Mar 20253:30 pmRNSHolding(s) in Company
14th Mar 20257:00 amRNSNotice of Annual General Meeting; Accounts posting
4th Mar 20253:00 pmRNSHolding(s) in Company
12th Feb 20252:30 pmRNSDirector/PDMR Shareholding
10th Feb 20257:00 amRNSFull Year Results
12th Dec 20241:00 pmRNSHolding(s) in Company
10th Dec 20247:00 amRNSTrading update and notice of results
2nd Dec 20243:01 pmRNSTotal Voting Rights
2nd Dec 20243:00 pmRNSDirector/PDMR Shareholding
25th Nov 20244:37 pmRNSShareholder Communications
28th Oct 20247:00 amRNSBoard appointment
1st Oct 20247:00 amRNSTotal Voting Rights
23rd Sep 20247:00 amRNSAppointment of Chief Executive Officer
2nd Sep 20245:15 pmRNSDirector/PDMR Shareholding
2nd Sep 20245:00 pmRNSTotal Voting Rights
31st Jul 202410:45 amRNSTotal Voting Rights
31st Jul 202410:30 amRNSBlock listing Interim Review
29th Jul 20246:15 pmRNSDirector/PDMR Shareholding
1st Jul 20247:00 amRNSInterim Results
27th Jun 20242:26 pmRNSDirector/PDMR Shareholding
23rd Apr 20241:38 pmRNSDirector/PDMR Shareholding
16th Apr 20242:56 pmRNSAGM Results Announcement
16th Apr 20247:00 amRNSAGM Trading Update & Board Update
3rd Apr 20247:00 amRNSDirector resignation
12th Mar 20247:00 amRNSDirector declaration
29th Feb 20247:00 amRNSTotal Voting Rights
8th Feb 20244:41 pmRNSHolding(s) in Company
8th Feb 20244:27 pmRNSDirector/PDMR Shareholding
5th Feb 20247:00 amRNSResults for the year ended 30 November 2023
1st Feb 20247:00 amRNSBlock listing Interim Review
19th Dec 202310:25 amRNSHolding(s) in Company
5th Dec 20237:00 amRNSTrading Update & Acquisition
4th Dec 202312:00 pmRNSHolding(s) in Company
25th Sep 202310:00 amRNSDirector/PDMR Shareholding
12th Sep 20237:00 amRNSNine Month Trading Update
21st Aug 20237:00 amRNSDirector/PDMR Shareholding
17th Jul 20237:00 amRNSAcquisition completion
7th Jul 20234:00 pmRNSBlock Listing Application
3rd Jul 20237:00 amRNSInterim Results
26th Jun 20237:00 amRNSBoard Change
21st Jun 20234:22 pmRNSHolding(s) in Company
21st Jun 20237:00 amRNSDirector/PDMR Shareholding
15th Jun 20237:00 amRNSBlock listing Interim Review
4th May 20237:00 amRNSAcquisitions
18th Apr 202312:51 pmRNSAGM resolutions
18th Apr 20237:00 amRNSAGM Trading Update
31st Mar 20234:00 pmRNSTotal Voting Rights
22nd Mar 20233:03 pmRNSGrant of options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.